Moreover, two phase I trials are currently evaluating the dual immune checkpoint blockade of LAG-3 and PD-1 (NCT03005782) and TIM-3 and PD-L1 (NCT03099109) in patients with HCC. The gene discussed is LAG3; the disease is hepatocellular carcinoma.